Evidence map›Paper›PMID 33568508›Full record

ArticleJournal of virology2021

Immune Responses and Viral Persistence in Simian/Human Immunodeficiency Virus SHIV.C.CH848-Infected Rhesus Macaques.

Widade Ziani, Anya Bauer, Hong Lu, Xiaolei Wang, Xueling Wu, Katharine J Bar, Hui Li, Dongfang Liu, George M Shaw, Ronald S Veazey and 1 more

Open access · hybridAbstract read
In one paragraph

Article in Journal of virology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.4field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. In vivo evolution of env in SHIV-AD8Molecular therapy : the journal of the American Society of Gene Therapy · 2025
    Article
  3. Review
  4. Review
  5. Article
  6. EfficientFrontiers in immunology · 2023
    Article
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Widade Ziani *Tulane National Primate Research Center, Tulane University School of Medicine, Covington, Louisiana, USA.
Anya Bauer *Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.ORCID 0000-0002-5793-0079
Hong LuAaron Diamond AIDS Research Center, Columbia University Vagelos College of Physicians and Surgeons, New York, New York, USA.
Xiaolei WangTulane National Primate Research Center, Tulane University School of Medicine, Covington, Louisiana, USA.
Xueling WuAaron Diamond AIDS Research Center, Columbia University Vagelos College of Physicians and Surgeons, New York, New York, USA.
Katharine J BarDepartment of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Hui LiDepartment of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Dongfang LiuDepartment of Pathology, Immunology and Laboratory Medicine, Rutgers University-New Jersey Medical School, Newark, New Jersey, USA.
George M ShawDepartment of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Ronald S VeazeyTulane National Primate Research Center, Tulane University School of Medicine, Covington, Louisiana, USA.
Huanbin XuTulane National Primate Research Center, Tulane University School of Medicine, Covington, Louisiana, USA hxu@tulane.edu.ORCID 0000-0003-1742-0979
Tulane University · USUniversity of Pennsylvania · USAaron Diamond AIDS Research Center · USRutgers, The State University of New Jersey · US

Funding

Tulane NPRC SPF Sheltered Outdoor Enclosure ExpansionP51OD011104 · OD · TULANE UNIVERSITY OF LOUISIANA · PI L Lee HAMM · 2012 to 2026
$142.4M
Virus and Antibody Gene Sequencing CoreP01AI131251 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI Kevin Wiehe · 2017 to 2026
$40.7M
Impact of tuberculosis on the development and function of the immune system in SIV-infected infantsR01HD099857 · NICHD · TULANE UNIVERSITY OF LOUISIANA · PI KAUSHAL, DEEPAK, WANG, XIAOLEI · 2019 to 2023
$6.9M
HIV-1 Q23.17 Env: Engineering a novel immunogen to elicit broadly neutralizing antibodiesR01AI165080 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI GEORGE M SHAW · 2021 to 2026
$6.6M
Combining germline-targeting, B cell immunofocusing and Env-Ab coevolution strategies to induce HIV Envelope V2-apex broadly neutralizing antibodiesR61AI161818 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI ANDRABI, RAIEES AHMAD, SHAW, GEORGE M · 2021 to 2023
$4.7M
Novel strategies for eliminating HIV reservoirs in lymphoid tissuesR01DE025432 · NIDCR · TULANE UNIVERSITY OF LOUISIANA · PI XU, HUANBIN · 2015 to 2019
$4.0M
Targeting 5' leader-encoded defective ribosomal products for HIV T cell vaccinesR01AI118549 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI SHAW, GEORGE M · 2016 to 2020
$3.6M
Reverse Vaccinology in SHIV Infected Macaques as a Molecular Guide for HIV-1 Vaccine DesignR01AI160607 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI SHAW, GEORGE M · 2021 to 2024
$3.2M
Development of the neonatal mucosal immune system in nonhuman primatesR01AI099795 · NIAID · TULANE UNIVERSITY OF LOUISIANA · PI WANG, XIAOLEI · 2012 to 2016
$2.9M
Novel HIV-1 Env trimer probes for efficient isolation of broadly neutralizing antibodiesR01AI122953 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI WU, XUELING · 2016 to 2019
$2.6M
Deep Sequencing to Identify B-Cell Precursors of HIV-1 Neutralizing AntibodiesR01AI114380 · NIAID · AARON DIAMOND AIDS RESEARCH CENTER · PI WU, XUELING · 2014 to 2018
$2.6M
Early Immune Development and Function in Neonates Exposed to Maternal HIV InfectionR01AI147372 · NIAID · TULANE UNIVERSITY OF LOUISIANA · PI XU, HUANBIN · 2019 to 2021
$1.5M
NIAID NIH HHS P01 AI131251NIAID NIH HHS R01 AI099795NIAID NIH HHS R01 AI114380NIAID NIH HHS R01 AI118549NIAID NIH HHS R01 AI122953NIAID NIH HHS R01 AI147372NIAID NIH HHS R01 AI160607NIAID NIH HHS R01 AI165080NIAID NIH HHS R61 AI161818NICHD NIH HHS R01 HD099857NIDCR NIH HHS R01 DE025432NIH HHS P51 OD011104
6 · The paper itself

Abstract

Chimeric simian/human immunodeficiency viruses (SHIVs) are widely used in nonhuman primate models to recapitulate human immunodeficiency virus (HIV) infection in humans, yet most SHIVs fail to establish persistent viral infection. We investigated immunological and virological events in rhesus macaques infected with the newly developed SHIV.C.CH848 (SHIVC) and treated with combined antiretroviral therapy (cART). Similar to HIV/simian immunodeficiency virus (SIV) infection, SHIV.C.CH848 infection established viral reservoirs in CD4

Indexed as

Disease Models, AnimalHIV InfectionsSimian Acquired Immunodeficiency SyndromeAnimalsAntibodies, NeutralizingAnti-Retroviral AgentsCD4-Positive T-LymphocytesHIV-1HumansMacaca mulattaSimian Immunodeficiency VirusViral LoadViremiaAntibodies, NeutralizingAnti-Retroviral Agentsautologous neutralizing Absautologous neutralizing Abs and evolutionevolutionpersistent infectionSHIVviral reservoirs

Identifiers

PMID33568508
PMCPMC8104099
OpenAlexW3128729864

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.